BCM
DFTX

Bayesian Capital Management’s Definium Therapeutics DFTX Stock Holding History

Bayesian Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,572
Closed -$33K – 864
2021
Q4 		$33K Buy
+1,572
New +$50.2K 0.01% 357

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

Bayesian Capital Management's DFTX Position: Q1 2022 in Review

Bayesian Capital Management sold out of Definium Therapeutics (DFTX) in Q1 2022, closing a stake of 1,572 shares — an estimated $33K sold.

Bayesian Capital Management first reported a position in DFTX in Q4 2021 and held it in 1 quarter. The position peaked at $33K in Q4 2021. 159 funds tracked by Wall St. Rank hold DFTX as of Q1 2022.

  • Bayesian Capital Management reported no remaining Definium Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 1,572 Definium Therapeutics shares in Q1 2022, an estimated $33K.
  • Bayesian Capital Management first reported a position in Definium Therapeutics in Q4 2021 and held it in 1 quarter.
  • Bayesian Capital Management's Definium Therapeutics position peaked at $33K in Q4 2021.
  • 159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2022.

Based on Bayesian Capital Management's 13F filing for Q1 2022, filed 16 May 2022.